Global Solid Phase Peptide Synthesis (SPPS) Vaccine Market Growth 2025-2031

The global Solid Phase Peptide Synthesis (SPPS) Vaccine market size is predicted to grow from US$ 121 million in 2025 to US$ 188 million in 2031; it is expected to grow at a CAGR of 7.6% from 2025 to 2031.

Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development.

Synthetic peptide vaccine is the most ideal and safe new vaccine, and it is also one of the main directions for the development of new vaccines for the prevention and control of infectious diseases and malignant tumors.

Solid-phase peptide synthesis (SPPS) is a mature production technology for peptides that are now widely used. The basic principle of this technique is that in insoluble porous support, the amino acid derivative rapidly assembles the peptide chain by successive reaction. An important consideration in peptide production is the use of protecting groups to avoid unnecessary side reactions. In solid-phase peptide synthesis, the two commonly used protection schemes are Fmoc/tBu and Boc/Bzl. The former uses the N-terminus of the base-unstable Fmoc, and the deprotection required for this method is generally mild. Boc/Bzl is advantageous when it is desired to reduce the aggregation of peptides in the production of peptides. In addition, since Fmoc is unstable to bases, Boc/Bzl approach is a better choice when synthesizing base-sensitive moieties. For some longer peptides, microwave-related peptide synthesis is a good choice for producing peptides with low levels of racemization, while chemical ligation, fragment condensation, are also preferable method for producing long peptides.

United States market for Solid Phase Peptide Synthesis (SPPS) Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Solid Phase Peptide Synthesis (SPPS) Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Solid Phase Peptide Synthesis (SPPS) Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Solid Phase Peptide Synthesis (SPPS) Vaccine players cover United Biomedical, CAHIC, Xinjiang Tecon, ISA Pharmaceuticals, Lytix Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Solid Phase Peptide Synthesis (SPPS) Vaccine Industry Forecast” looks at past sales and reviews total world Solid Phase Peptide Synthesis (SPPS) Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Solid Phase Peptide Synthesis (SPPS) Vaccine sales for 2025 through 2031. With Solid Phase Peptide Synthesis (SPPS) Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Solid Phase Peptide Synthesis (SPPS) Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Solid Phase Peptide Synthesis (SPPS) Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Solid Phase Peptide Synthesis (SPPS) Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Solid Phase Peptide Synthesis (SPPS) Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Solid Phase Peptide Synthesis (SPPS) Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Solid Phase Peptide Synthesis (SPPS) Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Solid Phase Peptide Synthesis (SPPS) Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
FMD Type O
FMD Type O+A
Others

Segmentation by Application:
Government Procurement
Direct Sales

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
United Biomedical
CAHIC
Xinjiang Tecon
ISA Pharmaceuticals
Lytix Biopharma
Merck
OncoTherapy Science
Circio
Stemline Therapeutics
Treos Bio

Key Questions Addressed in this Report

What is the 10-year outlook for the global Solid Phase Peptide Synthesis (SPPS) Vaccine market?

What factors are driving Solid Phase Peptide Synthesis (SPPS) Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Solid Phase Peptide Synthesis (SPPS) Vaccine market opportunities vary by end market size?

How does Solid Phase Peptide Synthesis (SPPS) Vaccine break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.